CN1317971A - 包含拉米夫定和阿巴卡维的抗病毒联合用药物 - Google Patents

包含拉米夫定和阿巴卡维的抗病毒联合用药物 Download PDF

Info

Publication number
CN1317971A
CN1317971A CN99811006A CN99811006A CN1317971A CN 1317971 A CN1317971 A CN 1317971A CN 99811006 A CN99811006 A CN 99811006A CN 99811006 A CN99811006 A CN 99811006A CN 1317971 A CN1317971 A CN 1317971A
Authority
CN
China
Prior art keywords
amino
combination medicine
preparation
hbv
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99811006A
Other languages
English (en)
Chinese (zh)
Inventor
N·A·布朗
L·D·康德雷
D·F·格雷
M·鲁宾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1317971A publication Critical patent/CN1317971A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN99811006A 1998-09-18 1999-09-17 包含拉米夫定和阿巴卡维的抗病毒联合用药物 Pending CN1317971A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9820417.5A GB9820417D0 (en) 1998-09-18 1998-09-18 Antiviral combinations
GB9820417.5 1998-09-18

Publications (1)

Publication Number Publication Date
CN1317971A true CN1317971A (zh) 2001-10-17

Family

ID=10839131

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99811006A Pending CN1317971A (zh) 1998-09-18 1999-09-17 包含拉米夫定和阿巴卡维的抗病毒联合用药物

Country Status (7)

Country Link
EP (1) EP1113803A1 (fr)
JP (1) JP2002526449A (fr)
KR (1) KR20010075202A (fr)
CN (1) CN1317971A (fr)
AU (1) AU6085099A (fr)
GB (1) GB9820417D0 (fr)
WO (1) WO2000016779A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221037A (zh) * 2010-11-12 2013-07-24 葛兰素惠尔康制造业私人有限公司 新药物组合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150447A0 (en) 2000-02-29 2002-12-01 Bristol Myers Squibb Co Pharmaceutical compositions containing entecavir
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
KR20050013628A (ko) * 2002-06-27 2005-02-04 메디비르 아베 아바카비르와 알로부딘의 공동상승 상호작용

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
CO4970782A1 (es) * 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221037A (zh) * 2010-11-12 2013-07-24 葛兰素惠尔康制造业私人有限公司 新药物组合物

Also Published As

Publication number Publication date
GB9820417D0 (en) 1998-11-11
AU6085099A (en) 2000-04-10
KR20010075202A (ko) 2001-08-09
JP2002526449A (ja) 2002-08-20
WO2000016779A1 (fr) 2000-03-30
EP1113803A1 (fr) 2001-07-11

Similar Documents

Publication Publication Date Title
CN1103593C (zh) 协同组合物
CN102670629B (zh) 用于联合抗病毒治疗的组合物和用途
US20090227608A1 (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
Jenns Importance of nausea
TW469132B (en) Antiviral combinations
CN1251993A (zh) N－取代的1,5－二脱氧－1,5－亚氨基－d－山梨醇化合物在治疗肝炎病毒感染的联合疗法中的用途
CN1178660C (zh) 抗病毒药物组合
CN1317971A (zh) 包含拉米夫定和阿巴卡维的抗病毒联合用药物
CN100475212C (zh) 用于治疗慢性淋巴细胞白血病的氮芥类似物和甲磺酸依马替尼的组合
US6432966B2 (en) Antiviral combinations
CN1738628B (zh) 用于联合抗病毒治疗的组合物和方法
CN1306430A (zh) 用于治疗hiv感染的含有vx478、叠氮胸苷和/或1592u89的复方制剂
CN1220604A (zh) 含咪唑衍生物的抗hiv组合物
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
WO2000016754A2 (fr) Combinaisons antivirales
WO2000018383A2 (fr) Combinaisons antivirales renfermant un ester isopropylique d'acide (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylique
MXPA01002673A (en) Antiviral combinations
CN1518983A (zh) 协同抗乙肝病毒（hbv）的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication